Tuesday, 18 September 2018
Latest news
Main » Revenue Estimates Analysis Of AcelRx Pharmaceuticals, Inc. (ACRX)

Revenue Estimates Analysis Of AcelRx Pharmaceuticals, Inc. (ACRX)

12 October 2017

Volume in the last session has increased compared with ACRX's average trading volume.

As of the latest earnings report the EPS was $-1.10 and is projected to be $-1.13 for the current year with 45,380,000 shares now outstanding. The stock rose 0.51% or $0.15 reaching $29.5 per share. About 930,082 shares traded. It has outperformed by 1.77% the S&P500. (ACRX) in trading session dated October 02, 2017. Its down 13.86% from 4.66 million shares previously. The SI to Acelrx Pharmaceuticals Incorporated's float is 15.04%. The company maintains price to book ratio of 3.94. AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has declined 14.24% since October 10, 2016 and is downtrending. It has underperformed by 10.31% the S&P500. The company has market cap of $245.05 million. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. It now has negative earnings. Its lead product candidates include ARX-04 and Zalviso, which utilizes sublingual sufentanil, delivered through a non-invasive route of administration.

Following trading activity for AcelRx Pharmaceuticals, Inc.(NASDAQ:ACRX), we can see that the stock has moved onto today's list of most actives. Therefore 75% are positive.

Trading volume for AcelRx Pharmaceuticals, Inc. was 3,134K on Wednesday. (NASDAQ:ZGNX) might see muted action given an ABR of 2.2 or Hold rating. The stock has "Buy" rating by TH Capital on Thursday, September 15. (NASDAQ:ACRX) by some 1,704,452 shares, 36 decreased positions by 4,793,764 and 17 held positions by 4,090,623. Analysts, on average, seem bullish as they suggest ZGNX is worth $10.37 more, giving a target price of $51.67 a share. In a transaction dated August 24, 2017, the shares were bought at an average price of $3, giving away a sum of $45,000. (ACRX) stock is considered to be Overbought?

Investors sentiment decreased to 0.75 in Q2 2017. ACRX has a 1-week performance of 0%.

Class Action Lawsuit Filed Against Maker Of Bump Stock Used In Shooting
Its voicemail box was not accepting messages and the company has not commented since the shooting took place. One of Eglet's attorneys representing plaintiffs in the case is State Senator Aaron Ford.

CEO, Angotti Vincent J., purchased 15,000 common shares of AcelRx Pharmaceuticals, Inc. Vanguard Group accumulated 1.36 million shares.

ACRX's institutional ownership stands at 39.70%. (NASDAQ:ACRX). Mark G. Edwards, Director reported the purchase of 5,000 shares of ACRX stock. Cornerstone Incorporated has 30,000 shares.

Brokerage firms now have a positive stance on shares of Cherokee Inc. Grt Capital Partners Ltd Liability holds 49,761 shares or 0.06% of its portfolio. AcelRx Pharmaceuticals, Inc.'s beta is 3.02 whilst the stock has an average true range (ATR) of 0.34. Ontario - Canada-based Royal Bank & Trust Of Canada has invested 0% in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). The company had Year Ago Sales of 3.37 Million. Deutsche National Bank & Trust Ag reported 293,770 shares. Kcg Holdings, Inc. controls 118,675 shares with a value of $255,000. The current consensus recommendation provided by covering analysts is 3.00. Therefore 33% are positive. Emerson Electric Co. had 59 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has "Neutral" rating by Buckingham Research given on Tuesday, December 13. There were 19 sold out positions, amounting to 615,954 shares. 86 funds opened positions while 383 raised stakes. This movement could be bad/good signal for few investors as firm is showing performance for the quarter as 144.44%. Meeder Asset Mgmt reported 1,673 shares. Longview Ptnrs (Guernsey) holds 12.62M shares. Caesarstone Ltd now has $1.01B valuation. It also reduced Johnson & Johnson (NYSE:JNJ) stake by 925 shares and now owns 51,093 shares. Pinnacle Entmt Inc New was reduced too.

Latest analyst recommendations could offer little help to investors.